Teresa Gonzalez Gallego-rekin lankidetzan egindako argitalpenak (12)

2004

  1. Interaction of angiotensin II with the angiotensin type 2 receptor inhibits the cardiac transient outward potassium current

    Cardiovascular Research, Vol. 62, Núm. 1, pp. 86-95

2003

  1. Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization

    Journal of Pharmacology and Experimental Therapeutics, Vol. 304, Núm. 2, pp. 862-873

  2. Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels

    Cardiovascular Research, Vol. 57, Núm. 3, pp. 660-669

  3. Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels

    Circulation, Vol. 107, Núm. 6, pp. 889-895

2002

  1. Assembly with the Kvβ1.3 subunit modulates drug block of hKv1.5 channels

    Molecular Pharmacology, Vol. 62, Núm. 6, pp. 1456-1463

  2. Effects of levobupivacaine, ropivacaine and bupivacaine on HERG channels: Stereoselective bupivacaine block

    British Journal of Pharmacology, Vol. 137, Núm. 8, pp. 1269-1279

  3. Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5)

    Cardiovascular Research, Vol. 56, Núm. 1, pp. 104-117

2001

  1. Bupivacaine effects on hkv1.5 channels are dependent on extracellular pH

    British Journal of Pharmacology, Vol. 134, Núm. 2, pp. 359-369

  2. Direct effects of candesartan and eprosartan on human cloned potassium channels involved in cardiac repolarization

    Molecular Pharmacology, Vol. 59, Núm. 4, pp. 825-836

  3. Effect of bupivacaine and a novel local anesthetic IQB-9302, on human cardiac K+ channels

    Journal of Pharmacology and Experimental Therapeutics, Vol. 296, Núm. 2, pp. 573-583

  4. Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5)

    British Journal of Pharmacology, Vol. 132, Núm. 2, pp. 385-392

2000

  1. Effects of a quaternary bupivacaine derivative on delayed rectifier K+ currents

    British Journal of Pharmacology, Vol. 130, Núm. 2, pp. 391-401